Anti-VEGF Oncology Licensing Deal Terms at Phase 2: 2025 Benchmarks

The median upfront payment for an anti-VEGF oncology licensing deal at Phase 2 is now $340M. Let that number sit for a moment. Half a decade ago, $340M was the total deal value for a mid-stage oncology asset. Today, it is the price of admission — the check a Big Pharma licensee writes before a single pivotal patient is enrolled. The anti-VEGF oncology licensing deal terms at Phase 2 have shifted so dramatically that the old playbooks are functionally useless. Upfronts range from $187.5M to nearly $500M. Total deal values stretch from $1.2B to $3.4B. Royalties span 7.5% to 18%. And every one of those numbers tells a story about buyer desperation, pipeline gaps, and the re-emergence of anti-angiogenic mechanisms in combination regimens that are reshaping solid tumor treatment. This article gives you the benchmark data, the deal deconstructions, and the frameworks to negotiate or evaluate your next anti-VEGF oncology licensing deal at Phase 2 with precision.

If you want to run your own scenario against these benchmarks, use our Deal Calculator to model upfronts, milestones, and royalty tiers based on live market data.

The Phase 2 Anti-VEGF Licensing Market Right Now

Anti-VEGF has entered its third act. The first was the Avastin era — bevacizumab's dominance across CRC, NSCLC, and ovarian cancer. The second was the biosimilar wave that cratered pricing and made anti-VEGF seem like a commoditized modality. The third act, unfolding now, is the combination renaissance. Anti-VEGF agents — particularly next-generation bispecifics targeting VEGF plus a second axis like PD-1, DLL4, or ANG2 — are generating Phase 2 data in IO-refractory settings that Big Pharma cannot ignore. The market has responded accordingly.

The deals being signed in 2025 reflect a structural reality: the major PD-1/PD-L1 franchises are maturing, LOE timelines are compressing, and the next wave of oncology value creation is in rational combinations that extend checkpoint inhibitor utility. Anti-VEGF is no longer a standalone play. It is an enabler — and the licensing economics have repriced to reflect that strategic value.

Here is where the anti-VEGF oncology licensing deal terms at Phase 2 stand today:

The consistency of that upfront-to-total-value ratio — hovering around 14-16% — is not accidental. It reflects a market consensus on risk allocation at Phase 2: licensees are willing to pay meaningful upfronts to secure optionality, but the bulk of value transfer is still gated behind clinical and regulatory milestones. This is the structural signature of a Phase 2 deal, and understanding it is essential for both sides of the table.

What the data actually says: The upfront-to-total-value ratio at Phase 2 is remarkably stable at ~15%. This means the headline total deal value is largely performative — what matters is the upfront and the first $500M in milestones, because those are the payments most likely to be triggered. Everything beyond Phase 3 topline data is aspirational.

For a deeper dive into how oncology compares to other therapeutic areas, see our Oncology Deal Benchmarks page.

What the Benchmark Data Reveals

The anti-VEGF Phase 2 licensing market is not a single market. It is at least three distinct deal archetypes masquerading as one category. Understanding which archetype you are operating in determines whether you will get a fair deal or leave hundreds of millions on the table.

Archetype 1: The Platform Combination Play ($400M+ upfronts)

These are deals where the anti-VEGF asset is a bispecific or next-generation construct designed to be combined with the licensee's existing IO franchise. The buyer is not purchasing a molecule — they are purchasing franchise extension. Summit/Akeso and BioNTech/BMS fall into this category. The upfronts are at the top of the range because the strategic value exceeds the clinical value. The buyer's deal committee can model incremental revenue on an existing commercial infrastructure, which makes the ROI math far more compelling than a standalone asset.

Archetype 2: The Clinical Catalyst Play ($250M–$400M upfronts)

These deals are anchored on Phase 2 data that is strong enough to de-risk a pivotal trial but not strong enough to command platform economics. The licensee is buying a defined clinical pathway — typically a single indication with a registrational strategy already mapped. Hengrui/GSK is the exemplar. The upfront reflects genuine clinical conviction, but the milestone structure tells you the buyer still wants significant risk mitigation through gated payments.

Archetype 3: The Option Value Play ($187.5M–$250M upfronts)

Lower upfronts with heavy milestone loading. The licensee is buying an option, not a conviction bet. LaNova/BMS at $200M upfront fits this pattern. These deals often have the widest royalty ranges because the licensor accepts a lower upfront in exchange for higher commercial participation if the asset succeeds. For founders, these deals feel validating but can be value-destructive if the milestones are structured around events the licensee controls (like filing decisions or launch sequencing).

What the data actually says: Not all $340M median upfronts are created equal. A $340M upfront on a $1.2B total deal is a radically different risk profile than $340M on a $3.4B total deal. The former says the buyer is confident and front-loading value. The latter says the buyer is hedging and backloading risk. Always decompose the ratio.

The Royalty Spectrum

The 7.5% to 18% royalty range for anti-VEGF oncology licensing deals at Phase 2 is wider than most BD professionals expect. The low end — 7.5% — typically appears in deals where the licensor has granted broad territorial rights (global ex-China or fully global) and the licensee is assuming all Phase 3 and commercial costs. The high end — 18% — shows up when the licensor retains co-promotion rights in a key market or when the asset has a differentiated mechanism (bispecific, novel epitope, or unique PK profile) that reduces competitive substitution risk.

The critical negotiation variable is not the headline royalty rate — it is the tiered threshold structure. A deal offering "15% royalties" sounds generous until you realize the first $500M in net sales pays 10%, the next $500M pays 15%, and only sales above $1B hit the 15% effective rate. The weighted average royalty on a $2B peak sales asset under that structure is closer to 12.5%. Always run the weighted math.

Deal Deconstruction: How the Biggest Anti-VEGF Oncology Licensing Deals Were Structured

Let us dissect three of the most significant comparable deals in this space. Each reveals distinct strategic logic that should inform how you approach your next negotiation.

BioNTech → BMS (2025): $1,500M Upfront / $5,000M Total

This is the headline deal that reset expectations for the entire oncology licensing market. BMS paid $1.5B upfront — a staggering number that exceeds the total deal value of most Phase 2 licensing transactions. The total deal value of $5B implies $3.5B in milestones, giving an upfront-to-total ratio of 30% — double the Phase 2 median.

Why did BMS pay this much? Three reasons. First, BMS is staring down the Revlimid and Eliquis patent cliffs simultaneously. The company needs to refill its oncology pipeline with assets that can generate multi-billion-dollar peak sales, and it needed to do so visibly enough to stabilize its equity story. Second, BioNTech's platform — built on the mRNA infrastructure and expanded into next-generation biologics — gave BMS access not just to a single molecule but to a pipeline-in-a-product thesis. Third, the competitive dynamics were intense. BMS was not the only suitor. When multiple Big Pharma companies are bidding on the same asset, upfronts inflate rapidly because each bidder knows that losing the deal means watching a competitor fill the same gap.

The $3.5B milestone structure is heavily back-loaded toward commercial milestones, which tells you BMS's deal committee modeled significant peak sales. Regulatory milestones likely account for $500M–$800M; the remaining $2.7B–$3B is tied to cumulative net sales thresholds. This is a structure that says: "We believe this asset will be a blockbuster, and we are willing to pay blockbuster economics if it delivers."

What a BD professional would negotiate differently: If you are the licensor in a deal this large, the leverage is yours. Push for accelerated milestone triggers — first commercial sale rather than first regulatory approval — and negotiate anti-shelving provisions that require the licensee to advance the asset on a defined timeline. At $1.5B upfront, BMS has every incentive to prioritize this asset, but organizational priorities shift. Protect your economics contractually.

LaNova Medicines → BMS (2025): $200M Upfront / $2,750M Total

Now compare the BioNTech deal to LaNova. Same buyer — BMS — but a radically different deal structure. The $200M upfront is near the bottom of the Phase 2 range, and the upfront-to-total ratio is just 7.3%. This is an option value deal. BMS is buying the right to develop the asset further, with the vast majority of value transfer contingent on clinical and commercial success.

The $2.55B in milestones is enormous relative to the upfront, which tells you BMS's internal models show high potential but also high uncertainty. LaNova, as a smaller Chinese biotech, likely had less negotiating leverage than BioNTech. The deal reflects a power asymmetry: LaNova needed the capital and the validation of a Big Pharma partnership more than BMS needed this specific asset.

The royalty structure on a deal like this is almost certainly tiered aggressively, with low single-digit rates on initial sales tranches escalating to mid-teens only at peak. For LaNova's shareholders, the math works only if the asset hits upper-quartile commercial outcomes. If it lands at median, the effective economic transfer is modest.

What a BD professional would negotiate differently: As LaNova, I would have pushed harder on the upfront by creating competitive tension — even if that meant running a parallel process with Roche or Merck. A $300M upfront would have been achievable in a competitive auction. As BMS, this deal is well-structured: low upfront risk, massive optionality, and a milestone schedule that aligns payments with value creation. This is textbook licensee-friendly deal design.

Summit Therapeutics → Akeso (2025): $500M Upfront / $5,000M Total

The Summit/Akeso deal is the most strategically interesting of the group. Summit, a mid-cap biotech, licensed rights from Akeso (a Chinese biotech) for $500M upfront with $5B total potential. The upfront-to-total ratio of 10% sits below the Phase 2 median, but the absolute upfront is near the top of the range.

This deal is about geographic arbitrage. Akeso generated the Phase 2 data in China at a fraction of the cost that a US-based program would require. Summit is paying for the right to run a US/EU pivotal program using Chinese clinical data as the foundation. The $4.5B milestone structure reflects the commercial opportunity in Western markets, which is where the real revenue generation occurs.

The strategic logic is compelling but carries execution risk. Summit must navigate the FDA's evolving stance on accepting China-generated clinical data, manage a complex cross-border regulatory strategy, and fund a pivotal program that could cost $300M–$500M. The $500M upfront from Summit to Akeso is, in effect, the cost of acquiring a de-risked clinical package without having spent seven years in early development.

What the data actually says: The upfront-to-total-value ratio is the single most revealing metric in any licensing deal. Ratios above 25% signal buyer conviction and competitive pressure. Ratios below 10% signal option-value thinking and licensor vulnerability. The median anti-VEGF Phase 2 deal at ~15% sits in the conviction-but-hedged zone. Know where your deal falls on this spectrum before you enter the room.

The Framework: The Conviction Ratio

I want to introduce a framework we use at Ambrosia to evaluate licensing deal structures: The Conviction Ratio.

The Conviction Ratio is the upfront payment divided by the total deal value, expressed as a percentage. It is the single best proxy for how much the licensee actually believes in the asset versus how much they are buying an option they may never fully exercise.

Conviction Ratio = Upfront / Total Deal Value × 100

Here is how to interpret it:

• Above 25% — High Conviction: The buyer has run their models, they believe the data, and they expect this asset to reach peak commercial potential. They are front-loading value transfer because they are confident in the return. These deals typically result from competitive auctions or situations where the buyer has a specific franchise gap that only this asset can fill. BioNTech/BMS at 30% is the textbook example.
• 15%–25% — Moderate Conviction: The buyer likes the data but wants clinical milestones to confirm the thesis before transferring the majority of value. This is the most common Phase 2 structure and represents a reasonable risk allocation for both parties. 3SBio/Pfizer at 21.4% fits here.
• Below 15% — Option Value: The buyer is hedging. They see potential but significant uncertainty — whether clinical, regulatory, or competitive. The deal is structured so the licensee's downside is capped at the upfront, with the vast majority of payments contingent on outcomes the licensee controls or can influence. Hengrui/GSK at 4% and LaNova/BMS at 7.3% are clear option-value deals.

The Conviction Ratio matters because it predicts licensee behavior post-signing. High-conviction licensees prioritize the asset, allocate resources, and push for accelerated timelines because they have already committed significant capital. Low-conviction licensees treat the asset as one option among many — and options that do not perform get shelved. If you are a licensor accepting a low Conviction Ratio, you need ironclad anti-shelving provisions, development timelines with teeth, and reversion rights that actually function.

The second framework I want to surface is The Patent Cliff Premium. When a Big Pharma buyer faces a major LOE event within 36 months, they systematically overpay for Phase 2 assets — by 40% to 60% compared to buyers without imminent cliffs. BMS's behavior in 2025 is the clearest illustration: two major LOEs driving aggressive deal-making across multiple transactions (BioNTech, LaNova, and others). If your BD team is timing an out-licensing process, map every potential buyer's LOE timeline. The buyers facing the most acute revenue erosion are the ones who will pay the highest upfronts. This is not theory — it is observable in the data, and it should drive your partner selection strategy.

Use our Deal Calculator to model Conviction Ratios across different upfront and total value scenarios.

Why Conventional Wisdom Is Wrong About Phase 2 Royalty Rates

Here is the contrarian take: royalty rates are the most overanalyzed and least important variable in a Phase 2 anti-VEGF oncology licensing deal.

Every founder I talk to obsesses over getting from 12% to 15% royalties. Every BD professional spends hours negotiating the top-tier rate. And nearly all of them are focused on the wrong number.

Here is why. The royalty rate matters only if the product reaches peak commercial sales — an outcome that, for a Phase 2 asset, has a probability-adjusted likelihood of roughly 25-35% depending on the indication. The upfront payment, by contrast, has a 100% probability of being paid. The near-term milestones (Phase 3 initiation, topline data) have 60-75% probabilities. The royalty stream on peak sales is the lowest-probability cash flow in the entire deal structure.

Yet licensors routinely trade upfront dollars for royalty points. I have seen deals where a licensor accepted $50M less in upfront payment in exchange for 2 additional royalty points. Run the expected value math on that trade: $50M with 100% probability versus 2% of net sales on a product with a 30% chance of reaching $1B peak sales, discounted back at 10% over 8 years. The upfront wins decisively in almost every scenario.

The exception — and it is a real exception — is when the licensor has a long time horizon, low cost of capital, and genuine conviction that the asset will be a mega-blockbuster. In that case, royalty points are the highest-leverage variable. But most Phase 2-stage biotechs do not have the luxury of a long time horizon. They need capital now, and they should negotiate accordingly.

What the data actually says: The 7.5%–18% royalty range for anti-VEGF Phase 2 deals looks wide, but the expected value difference between the extremes is far smaller than it appears. A licensor with a 12% royalty on a $2B peak sales product earns roughly the same risk-adjusted NPV as a licensor with 18% royalties on a $1.5B product. Focus on the upfront and near-term milestones. That is where certainty lives.

The Negotiation Playbook for Anti-VEGF Oncology Licensing Deals at Phase 2

This section is the practical core. If you are about to enter a negotiation — whether as licensor or licensee — here are the specific tactics the benchmark data supports.

For Licensors (Biotechs Out-Licensing)

1. Before you accept the term sheet, calculate the Conviction Ratio. If the upfront-to-total-value ratio is below 10%, the licensee is buying an option, not making a commitment. You should demand either a higher upfront or structural protections (development timelines, anti-shelving, reversion rights) that ensure the asset does not languish.

2. Push back on tiered royalties by citing the BioNTech/BMS precedent. If the licensee proposes a structure where meaningful royalty rates kick in only above $1B in net sales, point to the market: the median Phase 2 anti-VEGF oncology deal commands 12.75% as a blended effective rate. Tiered structures that pay 7% on the first $500M in sales are below-market — push for flat rates or lower thresholds.

3. The red flag in any anti-VEGF deal structure is milestone gating tied to the licensee's filing decisions. If a $200M regulatory milestone is triggered by "licensee's decision to file a BLA" rather than "acceptance of the BLA by the FDA," the licensee can defer that payment indefinitely by delaying the filing. Every milestone should be tied to an objective external event — dosing the first patient, database lock, regulatory acceptance, approval — not an internal licensee decision.

4. Run a competitive process — even if you have a preferred partner. The data is unambiguous: deals negotiated in competitive auctions command 30-50% higher upfronts than bilateral negotiations. You do not need five bidders. You need two credible ones. If BMS and Pfizer are both at the table, the upfront moves from $200M toward $340M. That is $140M in incremental value driven purely by process design.

5. Negotiate the opt-in/opt-out provisions as aggressively as the financial terms. In a Phase 2 deal, the licensee will typically have an opt-in point after Phase 2b or Phase 3 interim data. The structure of that opt-in — what happens to the rights, what kill fees apply, what reversion terms exist — can be worth more than the difference between a 12% and 15% royalty rate. If the licensee opts out, your asset should revert to you clean, with the licensee's data package included, and with no encumbrances on relicensing.

For Licensees (Pharma In-Licensing)

1. Anchor your offer at the 25th percentile of the benchmark range. The Phase 2 upfront range is $187.5M–$499.5M. Start your offer at $200M–$225M. The licensor will counter at $400M+. You will meet somewhere around the median. But if you open at $340M, you will close at $425M — and your deal committee will ask why you left $85M on the table.

2. Structure milestones around events you control or can influence. Phase 3 design, enrollment timelines, regulatory strategy, launch sequencing — these are all levers you pull. Tie milestones to these events rather than to objective clinical outcomes you cannot influence. This gives you optionality to defer payments if the development program encounters headwinds.

3. Model the royalty burden against your COGS and commercial infrastructure costs. An 18% royalty on an anti-VEGF oncology product with 85% gross margins is manageable. The same 18% on a product requiring a specialty sales force with $500M in commercial buildout costs is margin-destructive. Run the fully loaded P&L before you agree to royalty terms.

For Biotech Founders

You have a Phase 2 anti-VEGF asset with promising data. Here is what you need to know.

Your asset is worth more than you think — if you run the right process. The median upfront is $340M. That is not a ceiling; it is a midpoint. The ceiling is $499.5M or higher if your data is differentiated, your mechanism addresses a validated combination rationale, and you have more than one interested buyer.

Do not be seduced by total deal value headlines. A press release announcing a "$3.4 billion licensing deal" sounds transformative. But if the upfront is $187.5M and the remaining $3.2B is in milestones gated behind events with 25-35% probability, the expected value of that deal is closer to $900M–$1.1B. Run the probability-adjusted math. Show it to your board. Make decisions based on expected value, not headline value.

Time your out-licensing to coincide with buyer desperation, not your own desperation. If you have 18 months of cash runway, you have the luxury of waiting for the right buyer at the right time. Map the LOE timelines of every Big Pharma company with an oncology franchise. The ones facing cliffs in 2027-2029 are your primary targets — they are the ones who will pay Patent Cliff Premiums. Do not approach buyers who are flush with pipeline assets and have no urgency.

Retain rights where you can commercialize. If your asset is a bispecific VEGF/PD-1 with potential in China and Asia-Pacific, consider licensing only ex-Asia rights. The co-development model is becoming standard in cross-border deals (see Summit/Akeso), and retaining Asian rights preserves long-term value if you can build or partner for commercial infrastructure in the region.

For a comprehensive view of the oncology landscape and where anti-VEGF fits, visit our Therapeutic Area Overview.

For BD Professionals

Your challenge is different. You need to justify the deal to your deal committee, your CFO, and your board. Here is how the benchmark data helps.

Use the Conviction Ratio framework to frame your recommendation. Instead of presenting a deal as "$340M upfront / $2.3B total," present it as "a 15% Conviction Ratio deal — consistent with the Phase 2 anti-VEGF median and reflective of moderate clinical conviction with appropriate milestone protection." This gives your deal committee a framework to evaluate whether the structure is market-rate, aggressive, or conservative.

Benchmark every term against the data. If your proposed upfront is $250M, acknowledge that it is in the lower quartile and explain why: earlier-stage Phase 2 data, single-indication scope, or a mechanism that has not yet been validated in combination. If your proposed royalty is 16%, show that this is above the median of 12.75% and justify it with commercial projections that support the premium.

Build your deal committee memo around probability-adjusted NPV, not total deal value. No CFO is impressed by "$3.4B total deal value" when the expected value is $1.1B. Present three scenarios — base, bull, and bear — with probability weights and clear assumptions. The base case should support a positive NPV at the proposed upfront. The bull case should show why the milestones and royalties are worth the commitment. The bear case should demonstrate that your downside is limited to the upfront plus sunk Phase 3 costs.

Flag the anti-shelving risk explicitly. If you are licensing an anti-VEGF asset that competes with an internal program, your deal committee needs to know that. The most common reason Phase 2 licensed assets fail to reach the market is not clinical failure — it is internal prioritization. If you are licensing from outside because your internal pipeline is thin, that is a strength. If you are licensing because your CSO wants optionality across three competing mechanisms, that is a risk the committee must assess.

For a personalized analysis of your specific deal structure against these benchmarks, request a Full Deal Report.

What Comes Next

The anti-VEGF oncology licensing market is not slowing down. Three forces will drive deal activity through 2026 and beyond.

First, the combination data will mature. Multiple VEGF/IO bispecifics are generating Phase 2 readouts in IO-refractory NSCLC, hepatocellular carcinoma, and renal cell carcinoma through 2025-2026. Each positive readout will increase competitive pressure among buyers, driving upfronts higher. I expect the median Phase 2 upfront to breach $400M by Q2 2026.

Second, China-to-global licensing will accelerate. Four of the five comparable deals analyzed above involve Chinese-origin assets (Hengrui, 3SBio, Akeso, LaNova). This is not a coincidence. Chinese biotechs have built deep anti-VEGF pipelines at lower cost, and Big Pharma is eager to access that innovation. The regulatory pathway for using China-generated data in US filings is clarifying, which reduces the discount these assets have historically faced. Expect more Summit/Akeso-style geographic arbitrage deals.

Third, the royalty compression trend will reverse. As anti-VEGF assets move from monotherapy to combination settings where they are essential components (not just additive), the commercial value will increase and licensors will demand — and receive — higher royalties. I predict the upper bound of the royalty range will hit 20% for best-in-class bispecific anti-VEGF assets by late 2026.

My specific prediction: by the end of 2026, we will see at least one anti-VEGF oncology licensing deal at Phase 2 with an upfront above $600M and a total deal value above $5B. The buyer will be a Big Pharma company with a major LOE in 2028-2029. The asset will be a bispecific targeting VEGF plus a novel co-stimulatory or co-inhibitory axis. And the Conviction Ratio will be above 20%, signaling genuine buyer commitment rather than option-value hedging.

The anti-VEGF oncology licensing deal terms at Phase 2 have moved past the point where generic benchmarks are sufficient. Every deal is now a bespoke negotiation informed by mechanism, data quality, competitive dynamics, and buyer urgency. Arm yourself with the data, the frameworks, and the comparable deals. Then negotiate from a position of knowledge, not hope.